212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mary Maluccio, MD, MPH, FACS
Advertisement
Articles by Mary Maluccio, MD, MPH, FACS
Advertisement
Latest Updated Articles
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETsPublished: October 31st 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
2
Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer
3
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
4
FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM
5
